Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab

The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Koji Iinuma, Torai Enomoto, Kei Kawada, Shota Fujimoto, Takashi Ishida, Kimiaki Takagi, Shingo Nagai, Hiroki Ito, Makoto Kawase, Chie Nakai, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Koji Kameyama, Takuya Koie
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	nivolumab ipilimumab renal cell carcinoma neutrophil-to-lymphocyte ratio plate-let-to-lymphocyte ratio systemic immune inflammation index Medicine R
Acceso en línea:	https://doaj.org/article/dfd8c475531e40e1a066c9c7b071b541
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dfd8c475531e40e1a066c9c7b071b541
record_format	dspace
spelling	oai:doaj.org-article:dfd8c475531e40e1a066c9c7b071b5412021-11-25T18:01:46ZUtility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab10.3390/jcm102253252077-0383https://doaj.org/article/dfd8c475531e40e1a066c9c7b071b5412021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5325https://doaj.org/toc/2077-0383The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and ipilimumab (NIVO + IPI). We conducted a retrospective multicenter cohort study assessing patients with mRCC treated with NIVO + IPI at eight institutions in Japan. In this study, the follow-up period was median 14 months. The 1-year overall- and progression-free survival (PFS) rates were 89.1% and 63.1, respectively. The objective response rate (ORR) and disease control rate (DCR) were 41.9% and 81.4%, respectively. The 1-year PFS rates were 85.7% and 49.1% for NLR ≤ 2.8 and >2.8, respectively (<i>p</i> = 0.005), and 75.5% and 49.7% for PLR ≤ 215.6 and >215.6, respectively (<i>p</i> = 0.034). Regarding SII, the 1-year PFS rates were 90.0% and 54.8% when SII was ≤561.7 and >561.7, respectively (<i>p</i> = 0.023). Therefore, NLR, PLR, and SII levels in mRCC patients treated with NIVO + IPI may be useful in predicting oncological outcomes.Koji IinumaTorai EnomotoKei KawadaShota FujimotoTakashi IshidaKimiaki TakagiShingo NagaiHiroki ItoMakoto KawaseChie NakaiKota KawaseDaiki KatoManabu TakaiKeita NakaneKoji KameyamaTakuya KoieMDPI AGarticlenivolumabipilimumabrenal cell carcinomaneutrophil-to-lymphocyte ratioplate-let-to-lymphocyte ratiosystemic immune inflammation indexMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5325, p 5325 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nivolumab ipilimumab renal cell carcinoma neutrophil-to-lymphocyte ratio plate-let-to-lymphocyte ratio systemic immune inflammation index Medicine R
spellingShingle	nivolumab ipilimumab renal cell carcinoma neutrophil-to-lymphocyte ratio plate-let-to-lymphocyte ratio systemic immune inflammation index Medicine R Koji Iinuma Torai Enomoto Kei Kawada Shota Fujimoto Takashi Ishida Kimiaki Takagi Shingo Nagai Hiroki Ito Makoto Kawase Chie Nakai Kota Kawase Daiki Kato Manabu Takai Keita Nakane Koji Kameyama Takuya Koie Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
description	The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and ipilimumab (NIVO + IPI). We conducted a retrospective multicenter cohort study assessing patients with mRCC treated with NIVO + IPI at eight institutions in Japan. In this study, the follow-up period was median 14 months. The 1-year overall- and progression-free survival (PFS) rates were 89.1% and 63.1, respectively. The objective response rate (ORR) and disease control rate (DCR) were 41.9% and 81.4%, respectively. The 1-year PFS rates were 85.7% and 49.1% for NLR ≤ 2.8 and >2.8, respectively (<i>p</i> = 0.005), and 75.5% and 49.7% for PLR ≤ 215.6 and >215.6, respectively (<i>p</i> = 0.034). Regarding SII, the 1-year PFS rates were 90.0% and 54.8% when SII was ≤561.7 and >561.7, respectively (<i>p</i> = 0.023). Therefore, NLR, PLR, and SII levels in mRCC patients treated with NIVO + IPI may be useful in predicting oncological outcomes.
format	article
author	Koji Iinuma Torai Enomoto Kei Kawada Shota Fujimoto Takashi Ishida Kimiaki Takagi Shingo Nagai Hiroki Ito Makoto Kawase Chie Nakai Kota Kawase Daiki Kato Manabu Takai Keita Nakane Koji Kameyama Takuya Koie
author_facet	Koji Iinuma Torai Enomoto Kei Kawada Shota Fujimoto Takashi Ishida Kimiaki Takagi Shingo Nagai Hiroki Ito Makoto Kawase Chie Nakai Kota Kawase Daiki Kato Manabu Takai Keita Nakane Koji Kameyama Takuya Koie
author_sort	Koji Iinuma
title	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_short	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_full	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_fullStr	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_full_unstemmed	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_sort	utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab and ipilimumab
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/dfd8c475531e40e1a066c9c7b071b541
work_keys_str_mv	AT kojiiinuma utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT toraienomoto utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT keikawada utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT shotafujimoto utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT takashiishida utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT kimiakitakagi utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT shingonagai utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT hirokiito utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT makotokawase utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT chienakai utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT kotakawase utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT daikikato utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT manabutakai utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT keitanakane utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT kojikameyama utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab AT takuyakoie utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
_version_	1718411713031700480

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab

Ejemplares similares